MicroRNA-29c-3p in dual-labeled exosome is a potential diagnostic marker of subjective cognitive decline

Ying Li; Ming Xia; Shuang Meng; Di Wu; Sihai Ling; Xiali Chen; Chengeng Liu

doi:10.1016/j.nbd.2022.105800

Neurobiology of Disease (Sep 2022)

MicroRNA-29c-3p in dual-labeled exosome is a potential diagnostic marker of subjective cognitive decline

Ying Li,
Ming Xia,
Shuang Meng,
Di Wu,
Sihai Ling,
Xiali Chen,
Chengeng Liu

Affiliations

Ying Li: The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China; Clinical Laboratory of Air Force General Hospital, Chinese People's Liberation Army, Beijing 100142, China
Ming Xia: Clinical Laboratory of Minhang Hospital, Fudan University, Shanghai 201199, China
Shuang Meng: State Key Laboratory for Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Beijing 102206, China
Di Wu: Clinical Laboratory of Xuanwu Hospital, Captital Medcial University, Beijing 100053, China
Sihai Ling: The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China
Xiali Chen: The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China
Chengeng Liu: The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China; Corresponding author.

DOI: https://doi.org/10.1016/j.nbd.2022.105800
Journal volume & issue: Vol. 171
p. 105800

Abstract

Read online

Objective: The present study aimed to determine whether peripheral blood neural cell adhesion molecule (NCAM)/amphiphysin 1 dual-labeled exosomal proteins and microRNAs (miRs) might serve as a marker for the early diagnosis of Alzheimer's disease (AD). Methods: This observational, retrospective, multicenter study used a two-stage design conducted in Beijing and Shanghai, China. The subjects included 76 patients with subjective cognitive decline (SCD), 80 with amnestic mild cognitive impairment (aMCI), 76 with dementia of Alzheimer's type (AD), 40 with vascular dementia (VaD), and 40 controls in the discovery stage. These results were confirmed in the verification stage. The levels of Aβ42, Aβ42/40, T-Tau, P-T181-tau, neurofilament light chain (NfL), and miR-29c-3p in peripheral blood amphiphysin 1 single-labeled and NCAM/amphiphysin 1 dual-labeled exosomes were captured and detected by immunoassay. Results: In the discovery stage, the levels of Aβ42 and miR-29c-3p in peripheral blood NCAM/amphiphysin 1 dual-labeled exosome of the SCD group were significantly higher than those in control and VaD groups (all P < 0.05). The verification stage further confirmed the results of the discovery stage. Plasma NCAM/amphiphysin 1 dual-labeled exosomal miR-29c-3p showed a good diagnostic performance. The NCAM/amphiphysin 1 dual-labeled exosomal miR-29c-3p had the highest AUC for diagnosis of SCD. The levels of Aβ42, Aβ42/40, Tau, P-T181-tau, and miR-29c-3p in peripheral blood exosomes were correlated to those in CSF (all P < 0.05). The combination of exosomal biomarkers had slightly higher diagnostic efficiency than the individual biomarkers and that the exosomal biomarkers had the same diagnostic power as the CSF biomarkers. Conclusion: The plasma NCAM/amphiphysin 1 dual-labeled exosomal miR-29c-3p had potential advantages in the diagnosis of SCD.

Published in Neurobiology of Disease

ISSN: 0969-9961 (Print); 1095-953X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.journals.elsevier.com/neurobiology-of-disease

About the journal

Abstract

Keywords